Eptinezumab Reduced Acute Medication Use in Patients with Chronic Migraine and Medication-overuse Headache: Subgroup Analysis of PROMISE-2

Michael J. Marmura, MD

AHSAM 2020 - Poster session
Published on July 23, 2020 

1 minute
2 minute

This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.

Key messages

  • Eptinezumab reduced mean days of acute headache medication use— including triptans specifically—by ~50% over Weeks 1–12 in patients with CM and MOH (compared with ~25% with placebo), with results sustained or further decreased over Weeks 13–24.
  • Reductions in acute headache medication use were greater with eptinezumab than placebo across 24 weeks of treatment.
  • In patients diagnosed with both CM and MOH, eptinezumab treatment reduced acute headache medication use, including triptans, more than placebo.
  • Podcast by Michael J. Marmura, MD

Key messages

  • Eptinezumab reduced mean days of acute headache medication use— including triptans specifically—by ~50% over Weeks 1–12 in patients with CM and MOH (compared with ~25% with placebo), with results sustained or further decreased over Weeks 13–24.
  • Reductions in acute headache medication use were greater with eptinezumab than placebo across 24 weeks of treatment.
  • In patients diagnosed with both CM and MOH, eptinezumab treatment reduced acute headache medication use, including triptans, more than placebo.

Podcast by Michael J. Marmura, MD

Michael J. Marmura, MD
Associate Professor Director of Outpatient Operations, 
Jefferson Headache Center, Thomas Jefferson University Hospitals
Philadelphia, PA, Pennsylvania

 

Dr. Michael J Marmura MD is an associate professor of neurology at Thomas Jefferson University, and director of outpatient operations at the Jefferson Headache Center. He has been principal investigator for multiple clinical trials and author of several peer-reviewed articles and two textbooks. His particular areas of interest include migraine, olfaction in headache, guideline developement, pharmacology and cluster headache.

Michael J. Marmura, MD: Alder (Consulting) (Consulting Fees (e.g., advisory boards)) Allergan (Other Activities) (Research Grant) Amgen/Norvatis (Consulting) (Consulting Fees (e.g., advisory boards)) Amgen/Novartis (Speaking and Teaching) (Other Financial or Material Support) Antres (Consulting) (Consulting Fees (e.g., advisory boards))Cambridge (Other Activities) (Other Financial or Material Support) Devos Medical (Other Activities) (Other Financial or Material Support) ElectroCore (Speaking and Teaching) (Other Financial or Material Support)Eli Lilly (Consulting) (Consulting Fees (e.g., advisory boards)) eNeura (Other Activities) (Research Grant) Lilly (Speaking and Teaching) (Other Financial or Material Support) MedLink (Other Activities) (Other Financial or Material Support) Promius (Consulting) (Consulting Fees (e.g., advisory boards)) Teva (Other Activities) (Research Grant) Theranica (Consulting) (Consulting Fees (e.g., advisory boards)) Valeant (Other Activities) (Research Grant)

Headache
Clinical Trials

Scan to open on your mobile device